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INTRODUCTION
Atypical Hemolytic Uremic Syndrome: Background
 • Atypical hemolytic uremic syndrome (aHUS) is a genetic, progressive, life-threatening disease 
mostly resulting from chronic, uncontrolled complement activation. It is characterized by systemic 
thrombotic microangiopathy (TMA) leading to renal and other end-organ damage
 • Plasma exchange and infusion (PE/PI) has historically been used to manage aHUS1; however, 
evidence suggests that PE/PI offers no significant benefit over simple supportive therapy2,3 
 • Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT), a terminal complement inhibitor, 
is a humanized monoclonal antibody that binds with high affinity to the human C5 complement 
protein, blocking the generation of pro-inflammatory C5a and C5b-94 
 • Eculizumab is the first approved treatment for aHUS in pediatric and adult patients4–7
 • A single, global aHUS patient registry can maximize both physician and patient participation to best 
capture information on disease, safety, and efficacy data in a population with a very rare disease 
 • The global aHUS patient registry (ClinicalTrials.gov identifier: NCT01522183) was initiated in April 
2012 to prospectively capture postmarketing effectiveness and safety data on patients treated with 
eculizumab; the registry will record information on the progression of disease in all aHUS patients 
(whether treated with eculizumab or with other disease management strategies)
 • Furthermore, the registry fulfills postmarketing regulatory requirements by providing follow-up 
on the aHUS indication for eculizumab, and exemplifies the need for and benefit of successful 
partnering between sponsors and academia
OBJECTIVE
 • To report patient characteristics and describe important milestones achieved by patients enrolled in 
the aHUS registry from its inception (April 2012) through 1 year (April 1, 2013)
METHODS
Patient Eligibility Criteria
 • Inclusion criteria
 – Male or female patients of any age who have been diagnosed clinically with aHUS
 • With or without an identified complement regulatory factor genetic abnormality or  
anti-complement factor antibody (if tested)
 • ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif; 
C-terminal carboxy-terminal) >5%, if performed
 – Written informed consent from a patient or parent/legal guardian (if applicable as determined  
by the central Institutional Review Boards/Independent Ethics Committees) 
 • Exclusion criteria
 – HUS due only to Shiga toxin-producing Escherichia coli
Primary Outcome Measures
 • Proportion of patients who experience pre-specified events
 • Collection and evaluation of safety and efficacy data specific to the use of eculizumab in patients 
with aHUS
 • Time to first and subsequent occurrence of pre-specified events
 • Assessment of the long-term manifestations of TMA complications of aHUS; other clinical 
outcomes, including morbidity and mortality in patients with aHUS receiving eculizumab treatment 
or treated with other disease-management approaches
Data Collection
 • Data are collected at study enrollment and every 6 months thereafter and include the following:
 – Demographics
 – Medical and disease history
 – Symptomology
 – Targeted laboratory results (including genetic results)
 – TMA complications
 – Associated treatments and concomitant medications
 – Clinical and patient-reported outcomes
 – Safety of eculizumab and other aHUS treatments
 • To follow each patient and assess long-term outcomes for a minimum of 5 years, information from 
patient medical records is entered via a secure web portal and maintained anonymously
Registry Support
 • The registry is supported by Alexion Pharmaceuticals, Inc., with governance by an independent 
scientific advisory board (SAB) and national coordinators representing each participating country
 • Some key responsibilities of the SAB are to:
 – Provide scientific advice on aHUS registry-related matters
 – Propose, discuss, and evaluate program objectives with Alexion
 – Review and provide guidance on future amendments to the protocol, data variables to be 
collected, and case report refinements (all as appropriate)
 – Advise on analyses and scientific questions of interest
 – Review and provide feedback on publication goals and logistics
 – Contribute to the development of the publication plan
 – Establish and follow protocols for the review and approval of external requests for analyses and 
publications from individual investigators or national coordinators
 – Advise, counsel, and guide individuals on publications that utilize aHUS registry data and 
resources and/or use the aHUS registry name
 – Review publication drafts before submission to journals or public release
Inclusion for the Current Analysis
 • All enrolled patients with the following data were included in this analysis:
 – Ever treated with eculizumab or never treated with eculizumab
 – Registry enrollment date, date of birth, and sex must be available
 – For treated patients, date of first eculizumab treatment (if treated) must also be available
RESULTS
Patient Characteristics in Global aHUS Patient Registry
 • Tables 1–4 provide information on demographics, aHUS diagnosis, baseline clinical characteristics, 
and eculizumab treatment characteristics 
Countries Enrolling Patients Into aHUS Patient Registry (as of April 1, 2013)
 • Australia (n=7)
 • Austria (n=4)
 • Denmark (n=1)
 • Germany (n=2)
 • Israel (n=1)
 • Spain (n=8)
 • United Kingdom (n=5)
 • United States (n=25)
Breakdown of Enrolling Sites: Specialist Type 
 • Nephrologists (84%)
 • Hematologists (16%)
Breakdown of Enrolling Sites: Adult– Versus Pediatric–centric
 • Pediatric–centric sites (52%)
 • Adult–centric sites (47%) 
Table 1. Patient Demographics in Global aHUS Patient Registry (as of April 1, 2013)
Ever Treated With  
Eculizumab 
(n=32)
Never Treated With 
Eculizumab 
(n=21)
 
Total 
(N=53)
Mean age at registry enrollment (SD), years 38.1 (18.38) 33.0 (15.62) 36.1 (17.36)
Age at registry enrollment, n (%)
≥2 to <5 years
≥5 to <12 years
≥12 to <18 years
≥18 years
2 (6.3)
1 (3.1)
0 (0.0)
29 (90.6)
2 (9.5)
0 (0.0)
1 (4.8)
18 (85.7)
4 (7.5)
1 (1.9)
1 (1.9)
47 (88.7)
Sex, n (%)
      Female
      Male
22 (68.8)
10 (31.3)
7 (33.3)
14 (66.7)
29 (54.7)
24 (45.3)
Race, n (%)
Black
Caucasian
Latino
2 (6.3)
29 (90.6)
1 (3.1)
0 (0.0)
21 (100.0)
0 (0.0)
2 (3.8)
50 (94.3)
1 (1.9)
Year of registry enrollment, n (%)
2012
2013
17 (53.1)
15 (46.9)
4 (19.0)
17 (81.0)
21 (39.6)
32 (60.4)
aHUS, atypical hemolytic uremic syndrome; SD, standard deviation.
Table 2. aHUS Diagnosis Characteristics at Registry Entry (as of April 1, 2013)
Ever Treated With 
Eculizumab 
(n=32)
Never Treated With 
Eculizumab 
(n=21)
 
Total 
(N=53)
Mean age at initial symptoms (SD), years 37.7 (19.84) 
(n=29)
24.2 (13.63)
(n=15)
33.1 (18.94)
(n=44)
Mean age at diagnosis (SD), years 39.2 (19.00)
(n=28)
25.8 (15.97)
(n=15)
34.5 (18.95)
(n=43)
Family history of aHUS, n (%)
N/A
Yes
28 (87.5)
4 (12.5)
15 (71.4)
6 (28.6)
43 (81.1)
10 (18.9)
Any identified complement genetic mutation  
or auto-antibody, n (%)
N/A
No
Yes
 
3 (9.4)
20 (62.5)
9 (28.1)
 
7 (33.3)
7 (33.3)
7 (33.3)
 
10 (18.9)
27 (50.9)
16 (30.2)
aHUS, atypical hemolytic uremic syndrome; N/A, not available; SD, standard deviation.
Table 3. Baseline Clinical Characteristics of Patients at Registry Entry (as of April 1, 2013)
Ever Treated With 
Eculizumab  
(n=32)
Never Treated With 
Eculizumab  
(n=21)
 
Total  
(N=53)
Any prior kidney transplant, n (%)
Yes
 
4 (12.5)
 
1 (4.8)
 
5 (9.4)
Any prior dialysis, n (%)
Yes
 
15 (46.9)
 
4 (19.0)
 
19 (35.8)
Any prior plasma exchange/infusion, n (%)
Yes
 
17 (53.1)
 
4 (19.0)
 
21 (39.6)
Mean baseline eGFR (SD), mL/min/1.73 m2 10.6 (7.29)
(n=7)
86.8 (116.73)
(n=2)
27.6 (53.58)
(n=9)
eGFR, estimated glomerular filtration rate; SD, standard deviation.
Table 4. Characteristics of Patients Treated With Eculizumab at Registry Entry  
(as of April 1, 2013)
Ever Treated With 
Eculizumab (N=32)
Mean age at eculizumab treatment initiation (SD), years 38.1 (18.38)
(n=47)
Median dose at initiation of eculizumab (range), mg 900.0 (600–1200)
Mean time on eculizumab (SD), years 0.9 (0.85)
(n=31)
Any discontinuation of eculizumab, n (%)
No
Yes
 
30 (93.8)
2 (6.3)
Restarted eculizumab (among those who discontinued), n (%)
No
Yes
1 (50.0)
1 (50.0)
SD, standard deviation.
Milestones Achieved for the Global aHUS Patient Registry 
 • Figure 1 shows the milestones that have been reached to date since enrollment of the first patient 
on April 26, 2012
1st patient
enrolled
3rd
SAB 
100th patient
enrolled 
2nd
SAB 
1st
SAB 
50th patient
enrolled 
Global aHUS Patient Registry 
Apr 26
2012
Nov 4
2012
Jan 28
2013
Mar 22
2013
May 6
2013
Jun 1
2013
Figure 1. aHUS Patient Registry: a Timeline of Milestones Reached to Date
aHUS, atypical hemolytic uremic syndrome; SAB, scientific advisory board
CONCLUSIONS
 • Based on the limited enrollment at this time, reflecting the early stage of the registry, it would be 
premature to draw scientific conclusions from the data presented in this poster
 • The global aHUS patient registry is dedicated to increasing the understanding and awareness  
of aHUS disease history and progression
 • The results of analyses from collected data and outcomes provide an opportunity to optimize 
care and improve quality of life for aHUS patients
 • A single, global aHUS patient registry can maximize both physician and patient participation  
to best capture information on disease, safety, and efficacy data in a population with a very  
rare disease
 • New clinical sites are encouraged to participate
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